Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis

References

• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22(Suppl. 2):S133–144.
   PubMedGoogle Scholar
• Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996; 10:1570–1575.
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg IA. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int J Antimicrob Agents 2002; 19:299–311.
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006; 50:2122–2131.
   PubMed Web of Science ®Google Scholar
• van Etten EW, Otte-Lambillion M, van Vianen W, ten Kate MT, Bakker-Woudenberg AJ. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35:509–519.
   PubMed Web of Science ®Google Scholar
• Adedoyin A, Swenson CE, Bolcsak LE, . A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000; 44:2900–2902.
   PubMed Web of Science ®Google Scholar
• Bekersky I, Fielding RM, Dressler DE, . Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46:828–833.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Liao G, Hou J, . Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51:1253–1258.
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamamoto Y, Ueda Y, . Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 2006; 57:724–731.
   PubMed Web of Science ®Google Scholar
• Groll AH, Lyman CA, Petraitis V, . Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006; 50:3418–3423.
   PubMed Web of Science ®Google Scholar
• van Etten EW, ten Kate MT, Stearne LE, Bakker-Woudenberg IA. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995; 39:1954–1958.
   PubMed Web of Science ®Google Scholar
• Bowman JC, Abruzzo GK, Anderson JW, . Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45:3474–3481.
   PubMed Web of Science ®Google Scholar
• NCCLS. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. 2002; ; 28: :1––9..
   Google Scholar
• te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW, . Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. Antimicrob Agents Chemother 2005; 49:3341–3346.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41:733–738.
   PubMed Web of Science ®Google Scholar
• Nolting A, Derendorf H. Pharmacokinetic/pharmacodynamic modelling of antibiotics. Derendorf H, Hochhaus G, . Handbook of Pharmacokinetic/Pharmacodynamic Correlation. Boca Raton, FL: CRC Press, 1995: 363–388.
   Google Scholar
• Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003; 47:1179–1186.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, . Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol 2007; 45:109–111.
   PubMed Web of Science ®Google Scholar
• Mouton JW. Pharmacokinetics and pharmacodynamics of azoles. Nightingale C, Ambrose PG, Drusano GL, Mukisawa T, . Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Informa Health Care Inc, 2007: 327–354.
   Google Scholar
• Wiederhold NP, Tam VH, Chi J, . Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50:469–473.
   PubMed Web of Science ®Google Scholar
• Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J Antimicrob Chemother 1996; 38:215–225.
   PubMed Web of Science ®Google Scholar
• Van Etten EW, Stearne-Cullen LE, ten Kate M, Bakker-Woudenberg IA. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrob Agents Chemother 2000; 44:540–545.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations – Fungizone, amphotec (Amphocil), AmBisome, and Abelcet – against systemic murine aspergillosis. Antimicrob Agents Chemother 2004; 48:1047–1050.
   PubMed Web of Science ®Google Scholar
• Dotis J, Simitsopoulou M, Dalakiouridou M, . Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2006; 50:868–873.
   PubMed Web of Science ®Google Scholar
• Dotis J, Simitsopoulou M, Dalakiouridou M, . Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus. J Antimicrob Chemother 2008; 61:810–817.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Roilides E, Dotis J, . Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005; 49:1397–1403.
   PubMed Web of Science ®Google Scholar
• Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45:205–216.
   PubMed Web of Science ®Google Scholar
• Becker MJ, de Marie S, Fens MH, . Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J Antimicrob Chemother 2002; 49:813–820.
   PubMed Web of Science ®Google Scholar